Nephrology in October 2026: FDA approves ravulizumab for IgAN, plus ORIGIN 3, RAINIER, TELIGAN, and ATTACK data from Kidney Week.
|Articles|March 26, 2022
Endocrinology Month in Review: March 2022
Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. March's month in review features CGM news, calls for insulin co-pay caps, and info on the declining quality of US diets.
Advertisement
Editor's Note: Clicking in the center of the slide will redirect you to the affiliated article or video.
Advertisement
Related to this article
IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
Conference Preview: 2026 GOLD International COPD Conference
4
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
5